

## The CpG Island Methylator Phenotype: What's in a Name?

Laura A.E. Hughes<sup>1,2</sup>, Veerle Melotte<sup>2</sup>, Joachim de Schrijver<sup>6</sup>, Michiel de Maat<sup>3</sup>, Vincent T.H.B.M. Smit<sup>4</sup>, Judith V.M.G. Bovée<sup>4</sup>, Pim J. French<sup>5</sup>, Piet A. van den Brandt<sup>1</sup>, Leo J. Schouten<sup>1</sup>, Tim de Meyer<sup>6</sup>, Wim van Criekinge<sup>6</sup>, Nita Ahuja<sup>7</sup>, James G. Herman<sup>7</sup>, Matty P. Weijnenberg<sup>1</sup>, and Manon van Engeland<sup>2</sup>

### Abstract

Although the CpG island methylator phenotype (CIMP) was first identified and has been most extensively studied in colorectal cancer, the term "CIMP" has been repeatedly used over the past decade to describe CpG island promoter methylation in other tumor types, including bladder, breast, endometrial, gastric, glioblastoma (gliomas), hepatocellular, lung, ovarian, pancreatic, renal cell, and prostate cancers, as well as for leukemia, melanoma, duodenal adenocarcinomas, adrenocortical carcinomas, and neuroblastomas. CIMP has been reported to be useful for predicting prognosis and response to treatment in a variety of tumor types, but it remains unclear whether or not CIMP is a universal phenomenon across human neoplasia or if there should be cancer-specific definitions of the phenotype. Recently, it was shown that somatic *isocitrate dehydrogenase-1 (IDH1)* mutations, frequently observed in gliomas, establish CIMP in primary human astrocytes by remodeling the methylome. Interestingly, somatic *IDH1* and *IDH2* mutations, and loss-of-function mutations in ten-eleven translocation (*TET*) *methylcytosine dioxygenase-2 (TET2)* associated with a hypermethylation phenotype, are also found in multiple enchondromas of patients with Ollier disease and Mafucci syndrome, and leukemia, respectively. These data provide the first clues for the elucidation of a molecular basis for CIMP. Although CIMP appears as a phenomenon that occurs in various cancer types, the definition is poorly defined and differs for each tumor. The current perspective discusses the use of the term CIMP in cancer, its significance in clinical practice, and future directions that may aid in identifying the true cause and definition of CIMP in different forms of human neoplasia. *Cancer Res*; 73(19); 5858–68. ©2013 AACR.

### Introduction

Unraveling the complexities of the epigenetic code has been instrumental in advancing our understanding of cancer etiology. It is now clear that epigenetic modifications including aberrant DNA methylation, histone modifications, chromatin remodeling, and noncoding RNAs play a significant role in cancer development (1). Because such processes do not induce changes in the DNA sequence, but rather are self-propagating molecular signatures that are potentially reversible (2, 3), they provide novel targets for diagnosis and treatment strategies (1, 4, 5).

DNA hypermethylation of promoter-associated CpG islands of tumor suppressor and DNA repair genes, which leads to transcriptional silencing of these genes, has been the most studied epigenetic alteration in human neoplasia (1). Widespread CpG island promoter methylation, also referred to as the CpG island methylator phenotype (CIMP), was first identified (6) and has been extensively studied in colorectal cancer. Recently, we systematically reviewed the body of colorectal cancer CIMP research and concluded that because there is no universal standard or consensus with respect to defining CIMP, establishing the true prevalence of CIMP in colorectal cancer will be challenging until its biologic cause is determined (7).

Despite these limitations identified in colorectal cancer research, the term "CIMP" has been repeatedly used over the past decade to describe the increased prevalence of CpG island promoter methylation in other tumor types, including bladder (8), breast (9–11), endometrial (12, 13), gastric (14–19), glioblastoma (gliomas; refs. 20–22), hepatocellular (23–26), lung (27, 28), ovarian (29), pancreatic (30), prostate (31), and renal cell (32) cancers, as well as in leukemia (33–36), melanoma (37), duodenal adenocarcinomas (38), adrenocortical carcinomas (39), and neuroblastomas (40, 41). The primary purpose of these studies was to determine if CIMP is also present in these cancers, and if it can be used to distinguish between known phenotypes of the respective cancer type. However, in many cases, the observation of CIMP for a tumor results from a self-fulfilling definition, where a subgroup of tumors with a greater

**Authors' Affiliations:** Departments of <sup>1</sup>Epidemiology and <sup>2</sup>Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht; <sup>3</sup>Department of Surgery, Orbis Medical Center, Sittard-Geleen; <sup>4</sup>Department of Pathology, Leiden University Medical Center, Leiden; <sup>5</sup>Department of Neurology, Erasmus University Medical Center, Erasmus University, Rotterdam, the Netherlands; <sup>6</sup>Department of Mathematical Modeling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium; and <sup>7</sup>The Johns Hopkins University School of Medicine, Baltimore, Maryland

**Corresponding Author:** Manon van Engeland, Department of Pathology, GROW-School for Oncology and Developmental Oncology, Maastricht University Medical Center, PO. Box 616, 6200 MD, Maastricht, the Netherlands. Phone: 31-433874622; Fax: 31-433876613; E-mail: manon.van.engeland@mumc.nl

doi: 10.1158/0008-5472.CAN-12-4306

©2013 American Association for Cancer Research.

degree of DNA methylation than the remaining tumors constitutes CIMP.

Although CIMP has been associated with environmental and lifestyle factors (3, 42–48), the molecular basis for CIMP is only beginning to be explored. The first clues came from two studies showing that glioblastomas with a hypermethylator phenotype are associated with somatic mutations in *isocitrate dehydrogenase-1* (*IDH1*; refs. 20, 21), and that somatic mutations in *IDH1*, *IDH2*, as well as loss-of-function mutations in ten-eleven translocation (*TET*)-methylcytosine dioxygenase-2 (*TET2*) establish a hypermethylation phenotype in leukemia (49). These are the first indications for a molecular basis of CIMP, and provide an explanation for a very distinct set of tumors with increased levels of hypermethylated DNA. Consequently, these studies have provided a framework for understanding the interplay between genetic and epigenetic changes, and also raise questions about the causes and importance of CIMP in other tumor types. Is "CIMP" a universal phenomenon across human neoplasia caused by similar defects and characterized by similar hypermethylation, or are there tumor type-specific causes and tumor type-specific definitions of the phenotype?

Addressing these questions is essential for directing research at exploiting CIMP. Here, we discuss the evolution in our understanding of CIMP in various tumor types and how the recent characterization of the human cancer genome and epigenome may influence future research.

## CIMP: Roots in Colorectal Cancer

### Molecular characteristics of CIMP tumors

Before any discussion on CIMP, it is important to briefly describe CIMP in colorectal cancer, as much of the research surrounding CIMP in other cancer types is based on this body of evidence. It has been more than a decade since Toyota and colleagues first identified CIMP in colorectal cancer (6). Colorectal cancer tumors characterized by CIMP have distinctly different histology when compared with tumors derived from traditional adenoma-carcinoma pathway (50–53). An early event in CIMP tumors seems to be the <sup>V600E</sup>*BRAF* mutation (53). A tight association between the <sup>V600E</sup>*BRAF* mutation and CIMP, and mice data showing that the <sup>V600E</sup>*BRAF* mutation in the mouse gut induces increased DNMT3B expression, *de novo* methylation, and downregulation of specific CpG dinucleotides in *p16<sup>INK4A</sup>* exon 1, has been reported (54). However, there is no functional evidence supporting that the <sup>V600E</sup>*BRAF* mutation is a causal event for CIMP. Therefore, it remains possible that *BRAF* mutation is a surrogate marker for another causal gene. Furthermore, most CIMP colorectal cancers are characterized by promoter CpG island hypermethylation of the mismatch repair gene, *MLH1*, resulting in its transcriptional inactivation. Loss of *MLH1* is thought to cause microsatellite instability (MSI), a form of genetic instability characterized by length alterations within simple repeated microsatellite sequences of DNA (51, 55). Once *MLH1* is inactivated, the rate of progression to malignant transformation is rapid (53).

In 2006, a major advancement was made in CIMP research by using unsupervised hierarchical cluster analysis of methylation data; Weisenberger and colleagues identified a robust 5-

gene panel that recognized a distinct, heavily methylated subset of colorectal tumors that were also characterized by the <sup>V600E</sup>*BRAF* mutation and MSI (56). This panel proved the validity of the phenotype in colorectal cancer, which has been further substantiated and validated in a large, population-based sample (57). Since then, the combinations of genes in addition to those proposed by the Weisenberger and colleagues have been suggested as the "best" panel (58–61), but the idea that CIMP is tightly linked with the <sup>V600E</sup>*BRAF* mutation remains consistent in all studies. However, a cause or molecular mechanism for CIMP in colorectal cancer has not yet been identified, and thus the sensitivity and specificity of this panel for defining CIMP remains to be established. Another aspect that needs to be resolved is the question of whether colorectal cancer CIMP cases should be further subgrouped in CIMP-high and CIMP-low colorectal cancers (58–60, 62–64). Although CIMP-low colorectal cancers have been associated with *KRAS* mutations, this group has many clinical and pathologic features in common with non-CIMP, and consensus on how to define CIMP-low is currently lacking.

### CIMP translated to other cancer types

From the literature, it is evident that many studies have investigated CIMP on the premise that the phenotype and genes that quantify the phenotype are not cancer type specific, but rather universal. For example, studies involving breast and endometrial cancer have defined CIMP as "methylated multigenes in tumors" (11) and "when multiple genes are concurrently methylated" (13), respectively. The definition of "multiple" is defined by each investigator to provide separations into subgroups of patients. Furthermore, it is not uncommon for researchers investigating tumor types other than colorectal cancer to refer the study of Weisenberger and colleagues (56) as a rationale for studying CIMP as a marker of cancer, even though the results of that study were very specific for colorectal cancer, especially for tumors characterized by the <sup>V600E</sup>*BRAF* mutation.

In our recent review, we detailed the use of various techniques and multiple gene panels and cutoff thresholds used to classify a colorectal cancer tumor as CIMP-positive (7). Selection of gene panels and cutoff thresholds for defining CIMP and small sample sizes in other tumor types seems to be even more arbitrary than for colorectal cancer (Table 1). Studies in gastric cancer (14–19) have often been based on the "classic" gene panel first identified in colorectal cancer by Toyota and colleagues (6), before Weisenberger and colleagues (56). Studies in ovarian cancer (29), breast cancer (11), hepatocellular carcinoma (23, 26), and melanoma (37) have in part chosen gene panels based on observations from colorectal cancer or gastric cancer research. It is not our intention to imply that such studies are inherently flawed, but again, this type of selection assumes that CIMP is a universal process and not cancer specific.

Extensive studies of genetic and epigenetic changes in human cancers show that the transformation process differs greatly among tumors arising in different organs. Thus, if CIMP is ultimately organ or tissue specific, much of the true picture surrounding prevalence and prognostic value may not be

**Table 1.** Summary of studies of CIMP detection and status

Study	Study characteristics			Assessment of CIMP		
	Country	N	Gene panel <sup>a</sup>	Method	Marker threshold to assign CIMP-H	% CIMP-H <sup>b</sup>
Adrenocortical carcinomas Barreau and colleagues (39)	France	51	Genome-wide characterization of methylome and methylation-specific multiplex ligation-dependent probe of 33 genes identified in the genome-wide Infinium analysis	Infinium HumanMethylation27 arrays	Clustering analysis	16%
Bladder cancer Maruyama and colleagues (8)	United States	98	CHD1, RASSF1A, APC, CDH13, FHIT, RARB (RARβ), GSTP1, CDKN2A (p16), DAPK1 (DAPK), MGMT	MSP	≥4/10 Genes methylated	16%
Breast cancer Bae and colleagues (9)	Korea/United States	109	RASSF1A, SCGB3A1 (HIN1), TWIST1 (Twist), CCND2 (cyclin D2), RARB (RARβ), THRB (THRβ), CDH1 (E-cadherin), ESR1 (ER), BRCA1, GSTP1, BAX, RB1 (RB)	MSP	— <sup>c</sup>	Conclude that CIMP does not exist in breast cancer
Jing and colleagues (11)	China	50 Tumors	RASSF1A, BRCA1, CDKN2A (p16), CDH1, ESR1 (ER), RARB (RARβ), PTGS2 (COX-2), APC, DAPK1 (DAPK), FHIT	MSP	≥3/10 Genes methylated	78%
Fang and colleagues (10)	United States	50 Nontumor serum 39	Genome-wide characterization of methylome	EpTYPER system (Sequenom)	Characterized by the presence or absence of coordinate hypermethylation at a large number of genes	9% 44%
Endometrial cancer Whitcomb and colleagues (12)	United States	24	HOXA11, THBS1, THBS2, CTNNB1, VDR, MLH1, CDKN2A	COBRA	≥5/7 Genes methylated	"it exists"
Zhang and colleagues (13)	China	35	CDKN2A (P14), CDKN2A (P16), ESR1 (ER), PTGS2 (COX-2), RASSF1A	MSP	≥3/5 Genes methylated	49%
Duodenal adenocarcinoma Fu and colleagues (38)	United States	98	CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1	MethylLight	≥3/5 Genes methylated	27%
Gastric cancer Toyota and colleagues (19)	United States	56	MINT1, MINT2, MINT12, MINT25, MINT31	MSP	≥3/5 Genes methylated	41%
Oue and colleagues (18)	Japan	103	MINT1, MINT2, MINT12, MINT25, MINT31	MSP	≥3/5 Genes methylated	41%
Kim and colleagues (16)	South Korea	79	MINT1, MINT2, MINT12, MINT25, MINT31	COBRA	≥3/5 Genes methylated	24%
Etoh and colleagues (15)	Japan	105	CDKN2A (P16), MLH1 (hMLH1), THBS1 (THBS-1), MINT1, MINT2, MINT12, MINT31	MSP	≥3/7 Genes methylated	24%

(Continued on the following page)

**Table 1. Summary of studies of CIMP detection and status (Cont'd)**

Study	Study characteristics			Assessment of CIMP		
	Country	N	Gene panel <sup>a</sup>	Method	Marker threshold to assign CIMP-H	% CIMP-H <sup>b</sup>
An and colleagues (14)	United States	83	MINT1, MINT2, MINT25, MINT31	MSP	≥2/4 Genes methylated	31%
Kusano and colleagues (17)	Japan	78	MINT1, MINT2, MINT12, MINT25, MINT31	COBRA	≥4/5 Genes methylated	24%
Gilomas Noushmehr and colleagues (20)		272	Genome-wide characterization of the methylome	Infinium+ Golden Gate methylation assays MethylLight	Clustering analysis	9%
van den Bent and colleagues (22)	Europe (EORTC study 26851, the Netherlands)	208	SOWAHA (ANKRD43), HFE, MAL, LGALS3, FAS (FAS-1), (FAS-2), RHO (RHO-F)		DOCK5 hypomethylation + ≥5/7 genes methylated	8%
Hepatocellular cancer Shen and colleagues (25)	China, England, United States	68	Genome-wide characterization of the methylome	Infinium HumanMethylation27 arrays	Clustering analysis + Noushmehr definition	46%
Zhang and colleagues (26)	China	85	CDKN2A (p16), CACNA1G, PTGS2 (COX-2), ESR1 (ER), MINT1, MINT2, MINT27, MINT31	MSP	≥2/8 Genes methylated	38%
Cheng and colleagues (23)	China	50	CDKN2A (P14), CDKN2B (P15), CDKN2A (P16), TP53 (P53), RB1, ESR1 (ER), WTT1 (WTT), RASSF1A, MYC (c-Myc)	MSP	≥5/8 Genes methylated	70%
Leukemia Toyota and colleagues (36)	China	60	CDKN2A (P14), CDKN2B (P15), CDKN2A (P16), CDKN1A (P21), SYK, TIMP3 (TIMP-3), WTT1, CDH1 (E-cadherin), RASSF1A, RB1	MSP	≥4/10 Genes methylated	32%
Garcia-Manero and colleagues (33)	United States	36	ESR1 (ER), CACNA1G, MINT1, MINT2, CDKN2A (p16INK4A), THBS1, CDKN2B (p15INK4B), PTC1 (PTC1A, PTC1B), ABCB1 (MDR1), MYOD1 (MYOD), SDC4, GPR37, PITX2, MLH1	Bisulfite-PCR	≥8/14 Genes methylated	19%
Roman-Gomez and colleagues (35)	United States	80	ESR1 (ER), CDKN2B (p15), CDKN2A (p16), ABCB1 (MDR1), THBS1, THBS2, ABL1 (C-ABL), TP73 (p73), MYOD1 (MYF3), MME (CD10)	Bisulfite-PCR	≥3/10 Genes methylated	43%
	Spain	50	ADAMTS1 (ADAMTS-1), ADAMTS5 (ADAMTS-5), APAF1 (APAF-1), PPP1R1BB (ASFP-1), CDH1, CDH13, DAPK1 (DAPK), DIABLO, DKK3 (DKK-3), LATS1 (LATS-1), LATS2 (LATS-2), KLK10 (NES-1), CDKN2A (p14), CDKN2B (p15), CDKN2A (p16), CDKN1C (p57), TP73 (p73), PARK2 (PARK-2), PTEN, SFRP1/2/4/5 (SFRP1/2/4/5), PTPN6 (SHP-1), SYK, PYCARD (TMS-1), WIF1 (WIF-1)	MSP	≥3 Methylated genes	76%

(Continued on the following page)

**Table 1.** Summary of studies of CIMP detection and status (Cont'd)

Study characteristics				Assessment of CIMP		
Study	Country	N	Gene panel <sup>a</sup>	Method	Marker threshold to assign CIMP-H	% CIMP-H <sup>b</sup>
Roman-Gomez and colleagues (34)	Spain	54	38 Genes involved in cell immortalization and transformation	MSP	≥3 Methylated genes	63%
Figuera and colleagues (49)	United States	385	Genome-wide characterization of the methylome	Roche Nimblegen custom human promoter array covering 25,626 HpaII amplifiable fragments and MassArray Epityping	Clustering analyses	—
Lung cancer Suzuki and colleagues (28)	Japan	150	<i>TMEFF2 (HPT1)</i> , <i>SPARC</i> , <i>RPRM (Reprimo)</i> , <i>RBP1 (CRBP1)</i> , <i>RARB (RARβ)</i> , <i>RASSF1A</i> , <i>APC</i> , <i>CDH13</i> , <i>CDKN2A (p16<sup>INK4a</sup>)</i>	MSP	—	33%
Liu and colleagues (27)	China	60	<i>OGG1 (hOGG1)</i> , <i>VHL</i> , <i>RARB (RAR-β)</i> , <i>MLH1 (hMLH1)</i> , <i>SEMA3B</i> , <i>RASSF1A</i> , <i>ZMYND10 (BLU)</i> , <i>FHIT</i>	MSP	≥4/8 Genes methylated	57%
Melanoma Tanemura and colleagues (37)	United States	122	<i>WIF1</i> , <i>TFPI2</i> , <i>RASSF1A</i> , <i>RARB (RARβ2)</i> , <i>SOC31</i> , <i>GATA4</i> , <i>MINT1</i> , <i>MINT2</i> , <i>MINT3</i> , <i>MINT12</i> , <i>MINT17</i> , <i>MINT25</i> , <i>MINT31</i>	MSP	—	—
Neuroblastoma Abe and colleagues (40)	Japan	140	17 Members of <i>PCDHB</i> family, 13 members of <i>PCDH</i> family, <i>MST1 (HLP)</i> , <i>DKFZp451127</i> , <i>CYP26C1</i>	qMSP	Cutoff >40% methylation of <i>PCDHB</i> family members	—
Abe and colleagues (41)	Germany	152	17 Members of <i>PCDHB</i> family, <i>MST1 (HLP)</i> , <i>CYP26C1</i>	qMSP	>60% Methylation of <i>PCDHB</i> family members and for samples with 40% to 60% <i>PCDHB</i> methylation, >10% <i>MST1 (HLP)</i> methylation and/or >70% <i>CYP26C1</i> methylation	33%
Ovarian cancer Stratthdee and colleagues (29)	Scotland	93	<i>BRCA1</i> , <i>HIC1</i> , <i>MLH1</i> , <i>CDKN2A (p16)</i> , <i>TERC (hTR)</i> , <i>CASP8</i> , <i>MINT25</i> , <i>MINT31</i> , <i>CDKN2B (p15)</i> , <i>TP73 (p73)</i>	MSP	Unclear, although they do make a conclusion about CIMP	Unclear, 71% of tumors showed methylation
Pancreatic cancer Ueki and colleagues (30)	United States	45	<i>RARB (RARβ)</i> , <i>THBS1</i> , <i>CACNA1G</i> , <i>MLH1</i> , <i>MINT1</i> , <i>MINT2</i> , <i>MINT31</i> , <i>MINT32</i>	MSP	≥4/8 Genes methylated	14%
Prostate cancer Maruyama and colleagues (31)	United States	101	<i>RARB (RARβ)</i> , <i>RASSF1A</i> , <i>GSTP1</i> , <i>CDH13</i> , <i>APC</i> , <i>CDH1</i> , <i>FHIT</i> , <i>CDKN2A (p16<sup>INK4a</sup>)</i> , <i>DAPK1 (DAPK)</i> , <i>MGMT</i>	MSP	—	—

Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; MSP, methylation specific PCR analysis; qMSP, quantitative methylation specific PCR analysis.

<sup>a</sup>Gene names are reported as HUGO approved gene symbols, between brackets the gene symbols used in the original study.

<sup>b</sup>CIMP-H refers to either CIMP or in the instance that a study reported three CIMP categories, CIMP-high.

<sup>c</sup>Data not reported.

1702 requrides 91. uo isenib /a jpd 8589:061.069Z/8589:61.6Z/jpd-epijp/seuacuey/6ro sjeunof/oeer/djtu uo.ij pepetioiwoc

recognized with the use of CIMP markers developed in another tumor type. For example, in a study of CIMP in endometrial cancer, genes were selected on the basis of their high degree of methylation in other malignancies, including colorectal cancer (13). However, a recent molecular characterization of endometrial tumors identified no <sup>V600E</sup>*BRAF* mutations in any of the 87 specimens considered (65). Therefore, selecting a CIMP panel tightly associated with *BRAF* mutation may not be entirely relevant to quantifying or identifying CIMP in endometrial tumors. Similarly, results from a recent study on duodenal adenocarcinomas suggest that *BRAF* mutations are not involved in duodenal tumorigenesis, MSI, or CIMP development (38). If one hypothesizes that CIMP is a general phenomenon, then the cause of CIMP should also be general and similar across different cancer types.

To assess just how universal CIMP is across tumor types requires genome-wide characterization of the methylome. This is a relatively new direction in epigenetic research, and to our knowledge, has only been reported for gliomas (20), leukemia (49), breast cancer (10), benign nonhereditary skeletal tumors such as enchondroma (66), as well as, most recently, renal cell carcinoma (32), melanoma (67), gastric cancer (68), and oral squamous cell carcinoma (69).

## CIMP: Genome-Wide Characterization of the Methylome

### Glioma

Promoter-associated hypermethylation has been commonly reported in gliomas (70–76), but it was not until 2010, when Noushmehr and colleagues used Illumina array platform technology, that a CIMP specific for a group of gliomas with distinct molecular and clinical characteristics was established (20). They referred to this cluster of tumors as "G-CIMP" to imply its specificity for this tumor type. G-CIMP loci were then validated with MethyLight technology, and perfect concordance with G-CIMP calls on the array platforms versus with the MethyLight markers was observed. Consequently, similar prevalence of the phenotype was shown, providing validation of the technical performance of the platforms and of the diagnostic marker panel. Furthermore, Noushmehr and colleagues showed that G-CIMP was very tightly associated with the somatic *IDH1* mutation, and validated this in an independent subset of tumors (20).

In 2012, additional evidence for a causal role of *IDH1* in generating CIMP was presented. Using immortalized human astrocytes, Turcan and colleagues showed that the mechanistic process behind this involves the *IDH1* mutation subtly remodeling the epigenome by modulating patterns of methylation on a genome-wide scale, thereby changing transcriptional programs and altering the differentiation state (21). The authors suggest that the activity of IDH may form the basis of an "epigenomic rheostat," which links alterations in cellular metabolism to the epigenetic state (21).

Mutations in *IDH1* and *IDH2* result in a reduced enzymatic activity toward the native substrate isocitrate. Mutant *IDH1* catalyzes the reduction of  $\alpha$ -ketoglutarate to 2-hydroxyglutarate (2-HG), a potential oncometabolite (77–80) affecting gene

expression via various mechanisms. This is first accomplished via competitive inhibition of  $\alpha$ -ketoglutarate-dependent dioxygenases including Jumonji-C domain-containing histone demethylases (JHDM), thereby altering histone methylation levels. In addition, 2-HG inhibits the TET family of 5-methylcytosine (5mC) hydroxylases that convert 5mC to 5-hydroxymethylcytosine (5hmC) via direct competition with  $\alpha$ -ketoglutarate resulting in an accumulation of 5mC and thereby potentially altering the expression levels of large numbers of genes (49, 80). Finally, a mechanism altering hypoxia-inducible factor (HIF) expression is involved (81).

In their recent study, Turcan and colleagues showed that the expression of wild-type *IDH1* caused hypomethylation at specific loci, suggesting that both the production of 2-HG and the levels of  $\alpha$ -ketoglutarate can affect the methylome (21). Furthermore, unsupervised hierarchical clustering of methylome data showed that the hypermethylated genes included both genes that underwent *de novo* methylation as well as genes that originally possessed low levels of methylation but subsequently acquired high levels of methylation. Control astrocytes did not undergo these methylome changes. Mutant *IDH1*-induced remodeling of the methylome was reproducible and resulted in significant changes in gene expression (21).

### Leukemia

For leukemia, the same story can be told. CIMP, defined by methylation of candidate genes, was reported in 2001 and 2002 (33, 36). However, the mutational and epigenetic profiling data of Figueroa and colleagues in acute myelogenous leukemia (AML) for the first time identified a causal relationship between *IDH1*, *IDH2*, and *TET2* mutations and (overlapping) hypermethylation profiles and global hypermethylation (49). Functional support for this relationship was provided *in vitro* in hematopoietic cells in which expression of mutant *IDH1* and *IDH2* leads to an increase in DNA methylation, indicating that *IDH1/2* and *TET2* mutations contribute to leukemogenesis through a shared mechanism that disrupts DNA methylation. *In vivo* evidence comes from a conditional *IDH1(R132H)* knockin mouse model, which develops increased numbers of early hematopoietic progenitors, splenomegaly, and anemia with extramedullary hematopoiesis. These alterations are accompanied by changes in DNA and histone methylation profiles (82).

### Enchondroma and spindle cell hemangioma

Supporting the hypothesis that *IDH1* mutation leads to DNA methylation, evidence shows that somatic mosaic mutations in *IDH1*, and to a lesser extent *IDH2*, cause enchondroma and spindle cell hemangioma in patients with Ollier disease and Maffucci syndrome (66, 83). These are rare skeletal disorders in which there is also an increased incidence of glioma (66). Using Illumina HumanMethylation27 BeadChips, Pansuriya and colleagues examined possible differences in methylation between enchondromas with and without *IDH1* mutations. Unsupervised clustering of the 2,000 most variable CpG methylation sites gave two subgroups, one of which showed an overall higher methylation at the examined CpG sites, and all but one enchondromas with an *IDH1* mutation were positive for this "CIMP" (83).

### IDH mutations in other cancer types

In addition to glioma (>70%), leukemia (AML: 15%–30%), enchondroma (87%), and spindle cell hemangioma (70%), somatic *IDH1* mutations are also found in sporadic chondrosarcoma (~50%; refs. 49, 84) and at lower frequencies in anaplastic thyroid carcinoma (11%; ref. 85), (intrahepatic) cholangiocarcinomas (10%–23%; refs. 86, 87), and melanoma (10%; ref. 88), whereas in other solid tumors *IDH1* mutations are infrequent (<5%) or absent (89, 90). Interestingly, the *IDH1/2* mutations in melanoma are also accompanied by a loss of 5hmC in melanoma progression (67). Therefore, it is interesting to speculate whether or not future research to establish the cause of CIMP in other cancer types should focus on genes that are functionally similar to the *IDH* family, such as *TET2*, or on totally different genes. More specifically, it remains uncertain whether CIMP in other cancer types is also caused by inhibition of the conversion of 5mC to 5hmC and subsequent demethylation or that other factors are responsible for the accumulation of 5mC. In addition to colorectal cancer, another tumor type lacking *IDH1/2* mutations, but with a putative CIMP phenotype, is breast cancer.

### Breast cancer

To date, research that has investigated CIMP in breast cancer has not been conclusive (9, 91–94), with some studies going so far as saying that CIMP does not exist in breast cancer as a truly defined phenotype (9). Recently, Fang and colleagues used unsupervised hierarchical clustering from data collected with the Infinium Human Methylation27 platform in an attempt to clarify this dispute (10). Two DNA methylation clusters in a sample of breast cancer with diverse metastatic behavior were identified. One cluster encompassed a portion of hormone receptor (HR)<sup>+</sup> tumors [defined as estrogen receptor (ESR1)<sup>+</sup>/progesterone receptor (PGR)<sup>+</sup>, cluster 2] and one encompassed tumors that were ESR1<sup>+</sup>/PGR<sup>+</sup> or ESR1<sup>-</sup>/PGR<sup>-</sup> (cluster 1). Cluster 2 tumors had a highly characteristic DNA methylation profile with high coordinate cancer-specific hypermethylation at a subset of loci, similar to the CIMP phenotype seen in colorectal cancer. They referred to this as "B-CIMP," and confirmed the composition of the phenotype through two independent clustering algorithms (10). Although intriguing, these results should be interpreted with caution. Only 39 tumors were examined in the genome-wide study, and 3 genes were chosen to validate the importance for outcome only. Furthermore, the definition for CIMP using these 3 genes could be interpreted as arbitrary, and the findings have yet to be validated in a separate cohort.

Nevertheless, this study provides interesting and considerable data for future studies. For the first time, the question of whether CIMP targeted the same genes in different human tumor types was examined by repeating the hierarchical clustering to assess colon cancer (C-CIMP) and gliomas (G-CIMP) in additional tumor samples. With this analysis, Fang and colleagues showed that there was large-scale consensus between CIMP genes from the three cancer-types. CIMP in these different malignancies seemed to target many of the same genes, suggesting a common mechanistic foundation. However, despite the observed similarities, there was not 100% overlap

between the polycomb group (PcG) targets that comprise the B-, C-, and G-CIMP, which may reflect a degree of tissue or organ specificity (10). Although this supports the idea that *IDH1* mutation has been determined as the cause of G-CIMP, this is not true for other cancers. The findings must be validated in additional cohorts before firm conclusions can be made.

### CIMP as a Prognostic Marker

Through their methodology, the studies of Fang and colleagues (10) and Noushmehr and colleagues (20) were able to clearly show distinct clinical characteristics of tumors characterized by B-CIMP and G-CIMP. For instance, B-CIMP tumors were associated with ESR1/PGR status, a lower risk of metastasis, and an improved clinical outcome (10). G-CIMP has been associated with improved survival, younger age at diagnosis, and histologic characteristics (20, 22). Furthermore, using the Infinium array, a recent methylome analysis in a study of patients with primary clear cell renal carcinoma showed that CIMP characterized a specific cluster of tumors associated with aggressiveness and patient outcome (32). Such findings reiterate that a major motivation for establishing whether CIMP is universal or cancer specific is because of its potential use as a prognostic marker.

Table 2 shows that CIMP is associated with both favorable and unfavorable prognosis, as well as different clinical characteristics, depending on the type of tumors. There are several possible explanations for these discrepancies. First, although CIMP has been identified in different types of cancer, it may simply not be a universal marker of good or bad prognosis. Second, as previously noted, it could be possible that for some cancers, the gene panels and cutoff thresholds used to define CIMP are not accurate for defining the "true" phenotype. It is interesting to observe that CIMP is associated with a favorable prognosis for colorectal cancer and gliomas, two cancer types for which extensive research has been conducted with respect to identifying genes that are associated with clinical and molecular features of the tumors, and in studies that included a relatively large number of cases (20, 57).

Moreover, it has been noted that the association of methylation at CIMP genes with good clinical outcome is not universally applicable to methylation at all genes. Methylation of specific candidate genes or groups of genes has been associated with poorer prognosis, and these genes may have an effect on tumor aggressiveness independent of CIMP (10).

### Conclusions and Future Perspectives

Much like what has been observed in the field of colorectal cancer research (7), the study of CIMP in other tumor types has been quite heterogeneous in terms of how the phenotype has been defined. Recent studies considering genome-wide characterization of the methylome in gliomas and leukemia have shown that CIMP is likely more than just a generic name to be used to describe aberrant methylation.

Although there is some overlap with respect to genes targeted by CIMP in colon cancer, breast cancer, and gliomas, and although *IDH1* and genes that affect the same (metabolic) pathway, such as *IDH2* and *TET2*, have been shown to be

**Table 2.** CIMP and clinicopathologic features of different cancers

Cancer type	Significant clinical associations	Prognosis
Adrenocortical carcinomas (39)		–
Bladder cancer (8)		–
Breast cancer (10)	Subset of hormone positive tumors (ESR1 <sup>+</sup> /PGR <sup>+</sup> )	+
Colorectal cancer (56)	Female Older age Proximal location MSI <i>BRAF</i> mutation	+
Duodenal adenocarcinomas (38)		
Endometrial cancer (12, 13)	Early stage COX-2 hypermethylation	–
Gastric cancer (14–19)	MSI Lymph node metastasis	±
Gliomas (20)	Younger age at diagnosis <i>IDH1</i> mutation	+
Hepatocellular carcinoma (23–26)	Serum $\alpha$ -fetoprotein (AFP) Metastasis TNM staging CIMP in serum	–
Leukemia (adult acute lymphocytic; ref. 33)	Younger age	
Leukemia (acute myeloid; ref. 36)	Younger age	
Leukemia (T-cell acute lymphoblastic; ref. 35)		+
Leukemia (childhood acute lymphoblastic; ref. 34)		–
Lung cancer (27, 28)		–
Melanoma (37)	Advanced stage	–
Neuroblastoma (40, 41)		–
Prostate cancer (31)	High preoperative serum (PSA) levels Advanced stage	–
Renal cell carcinoma (32)	Tumor aggressiveness	–

causally involved in the generation of CIMP in gliomas and leukemia, cancer-specific differences still exist and the cause of CIMP in the majority of cancer types remains to be identified. The causal relationship between somatic mutations in genes such as *IDH1*, *IDH2*, and *TET2* and altered genome-wide DNA methylation profiles generated by next-generation sequencing techniques is a promising clue on the cause of CIMP. The fact that these mutations impair histone demethylation and induce repressive histone methylation marks thereby blocking cell differentiation (95) provide clues on the complex relations between specific genetic alterations, CIMP, and clinical characteristics such as histologic features and prognosis.

In addition, analyzing the relationship between somatic mutations in chromatin remodeling genes and CIMP could yield interesting insights. For example, *AT-rich interactive domain-containing protein 1a* (*ARID1a*), a member of the switch/sucrose nonfermentable (SWI-SNF) complex, has been reported to be mutated and inactivated in a subset of gastrointestinal cancers, the majority of which also exhibit another characteristic of C-CIMP, namely MSI (96–98).

To unify the field and to establish a standard definition for CIMP, we present the following recommendations:

1. CIMP is not a single phenotype in all types of cancer. A simple variation from the standard nomenclature of

"CIMP" to make this distinction, such as "C-CIMP" for colorectal cancer CIMP, "G-CIMP" for glioma CIMP, "L-CIMP" for leukemia CIMP, and "B-CIMP" for breast cancer CIMP should be adopted for clarity.

2. Multiple reports suggest a third category of CIMP in colorectal cancer by dividing CIMP into CIMP-high and CIMP-low. Although CIMP-low has repeatedly been associated with *KRAS* mutations, this group has many clinical and pathologic features in common with non-CIMP, and thus without evidence that this is a distinct phenotype and without consensus on how to define CIMP-low, the use of CIMP-low should be discouraged.
3. A consensus meeting should be organized to:
  - a) Obtain recommended guidelines on the optimal CIMP marker panel for each tumor type. This includes the number of markers in the panel, the specific loci (genes) included, and the defined region examined for methylation in each gene.
  - b) Obtain recommended guidelines on the method to measure CIMP. If quantitative methods are needed for CIMP classification, defined cutoffs must be established for each marker for subsequent validation.



4. Once CIMP markers have been identified, they should be validated in large, independent, well-characterized patient series with clinical follow-up data (molecular pathologic epidemiology approach; refs. 99, 100).
5. A research effort for identifying the biologic cause of CIMP among tumor types should be implemented once standard criteria for CIMP are established and validated. Focus should be on establishing causal relationships to find the driver(s) of CIMP.
6. Dissemination of the recommended guidelines to the field, as was done for Bethesda MSI markers (101), is crucial in standardizing research in the field of CIMP.

Hopefully, these recommendations will help to establish the true causes, manifestation, and proper definitions of CIMP.

#### Disclosure of Potential Conflicts of Interest

W. van Criekinge is employed as CSO in MDX Health. J.G. Herman has a commercial research grant from MDX Health and is a consultant/advisory board member of the same. M. van Engeland has a commercial research grant from MDX Health. No potential conflicts of interest were disclosed by the other authors.

#### References

1. Esteller M. Epigenetics in cancer. *N Engl J Med* 2008;358:1148–59.
2. Bonasio R, Tu S, Reinberg D. Molecular signals of epigenetic states. *Science* 2010;330:612–6.
3. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. *Patholog Res Int* 2011; 902674.
4. Laird PW. The power and the promise of DNA methylation markers. *Nat Rev Cancer* 2003;3:253–66.
5. van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. Colorectal cancer epigenetics: complex simplicity. *J Clin Oncol* 2011;29: 1382–91.
6. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. *Proc Natl Acad Sci U S A* 1999;96:8681–6.
7. Hughes LA, Khalid-de Bakker CA, Smits KM, van den Brandt PA, Jonkers D, Ahuja N, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. *Biochim Biophys Acta* 2012;1825:77–85.
8. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. *Cancer Res* 2001;61:8659–63.
9. Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, et al. Hypermethylation in histologically distinct classes of breast cancer. *Clin Cancer Res* 2004;10:5998–6005.
10. Fang F, Turcan S, Rimmer A, Kaufman A, Giri D, Morris LG, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. *Sci Transl Med* 2011;3:75ra25.
11. Jing F, Yuping W, Yong C, Jie L, Jun L, Xuanbing T, et al. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. *Tumour Biol* 2010;31:321–31.
12. Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Goodfellow PJ. Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. *Clin Cancer Res* 2003;9:2277–87.
13. Zhang QY, Yi DQ, Zhou L, Zhang DH, Zhou TM. Status and significance of CpG island methylator phenotype in endometrial cancer. *Gynecol Obstet Invest* 2011;72:183–91.
14. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. *Clin Cancer Res* 2005;11:656–63.
15. Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. *Am J Pathol* 2004;164:689–99.
16. Kim H, Kim YH, Kim SE, Kim NG, Noh SH. Concerted promoter hypermethylation of hMLH1, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability. *J Pathol* 2003;200: 23–31.
17. Kusano M, Toyota M, Suzuki H, Akino K, Aoki F, Fujita M, et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. *Cancer* 2006;106:1467–79.
18. Oue N, Oshimo Y, Nakayama H, Ito R, Yoshida K, Matsusaki K, et al. DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. *Cancer Sci* 2003;94:901–5.
19. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. *Cancer Res* 1999;59:5438–42.
20. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* 2010;17: 510–22.
21. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature* 2012;483:479–83.
22. van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. *Clin Cancer Res* 2011;17:7148–55.
23. Cheng Y, Zhang C, Zhao J, Wang C, Xu Y, Han Z, et al. Correlation of CpG island methylator phenotype with poor prognosis in hepatocellular carcinoma. *Exp Mol Pathol* 2010;88:112–7.
24. Liu JB, Zhang YX, Zhou SH, Shi MX, Cai J, Liu Y, et al. CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis. *World J Gastroenterol* 2011;17:4718–24.

#### Authors' Contributions

**Conception and design:** L.A.E. Hughes, V.T.H.B.M Smit, P.A. van den Brandt, N. Ahuja, M.P. Weijnenberg, M. van Engeland

**Development of methodology:** L.A.E. Hughes, N. Ahuja, M.P. Weijnenberg, M. van Engeland

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** M.P. Weijnenberg

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** L.A.E. Hughes, J. de Schrijver, W. van Criekinge, N. Ahuja, J.G. Herman, M.P. Weijnenberg

**Writing, review, and/or revision of the manuscript:** L.A.E. Hughes, V. Melotte, J. de Schrijver, M. de Maat, V.T.H.B.M Smit, J.V.M.G. Bovée, P.J. French, P.A. van den Brandt, L.J. Schouten, T. de Meyer, W. van Criekinge, N. Ahuja, J.G. Herman, M.P. Weijnenberg, M. van Engeland

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** L.J. Schouten, M.P. Weijnenberg

**Study supervision:** P.A. van den Brandt, M.P. Weijnenberg, M. van Engeland

#### Acknowledgments

This study was financially supported by a Cancer Research Foundation Limburg grant (M. van Engeland, M.P. Weijnenberg, and P.A. van den Brandt). J.V.M.G. Bovée is supported by the Netherlands Organization for Scientific Research (917-67-315). P.J. French is supported by ZonMW project numbers 92003560, 40-41200-98-9051, 95110051, and stophersentumoren.nl.

Received November 21, 2012; revised June 5, 2013; accepted June 8, 2013; published OnlineFirst June 25, 2013.

25. Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. *J Natl Cancer Inst* 2002;94:755–61.
26. Zhang C, Li Z, Cheng Y, Jia F, Li R, Wu M, et al. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma. *Clin Cancer Res* 2007;13:944–52.
27. Liu Z, Zhao J, Chen XF, Li W, Liu R, Lei Z, et al. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer. *Lung Cancer* 2008;62:15–22.
28. Suzuki M, Shigematsu H, Iizasa T, Hiroshima K, Nakatani Y, Minna JD, et al. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of non-small cell lung cancer. *Cancer* 2006;106:2200–7.
29. Strathdee G, Appleton K, Iland M, Millan DW, Sargent J, Paul J, et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. *Am J Pathol* 2001;158:1121–7.
30. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. *Cancer Res* 2000;60:1835–9.
31. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. *Clin Cancer Res* 2002;8:514–9.
32. Arai E, Chiku S, Mori T, Gotoh M, Nakagawa T, Fujimoto H, et al. Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. *Carcinogenesis* 2012;33:1487–93.
33. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. *Clin Cancer Res* 2002;8:2217–24.
34. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Calasanz MJ, et al. CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. *Clin Cancer Res* 2006;12:4845–50.
35. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Prosper F, Heiniger A, Torres A. Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. *J Clin Oncol* 2005;23:7043–9.
36. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. *Blood* 2001;97:2823–9.
37. Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, Morton DL, et al. CpG island methylator phenotype predicts progression of malignant melanoma. *Clin Cancer Res* 2009;15:1801–7.
38. Fu T, Pappou EP, Guzzetta AA, Jeschke J, Kwak R, Dave P, et al. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. *Clin Cancer Res* 2012;18:4743–52.
39. Barreau O, Assie G, Wilmot-Roussel H, Ragazzon B, Baudry C, Perlemoine K, et al. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. *J Clin Endocrinol Metab* 2013;98:E174–84.
40. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. *Cancer Res* 2005;65:828–34.
41. Abe M, Westermann F, Nakagawara A, Takato T, Schwab M, Ushijima T. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. *Cancer Lett* 2007;247:253–8.
42. Curtin K, Slattery ML, Ulrich CM, Bigler J, Levin TR, Wolff RK, et al. Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. *Carcinogenesis* 2007;28:1672–9.
43. de Vogel S, Wouters KA, Gottschalk RW, van Schooten FJ, de Goeij AF, de Bruine AP, et al. Genetic variants of methylating enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2009;18:3086–96.
44. Hughes LA, van den Brandt PA, de Bruine AP, Wouters KA, Hulsmans S, Spiertz A, et al. Early life exposure to famine and colorectal cancer risk: a role for epigenetic mechanisms. *PLoS ONE* 2009;4:e7951.
45. Hughes LA, van den Brandt PA, Goldbohm RA, de Goeij AF, de Bruine AP, van Engeland M, et al. Childhood and adolescent energy restriction and subsequent colorectal cancer risk: results from the Netherlands Cohort Study. *Int J Epidemiol* 2010;39:1333–44.
46. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. *J Natl Cancer Inst* 2010;102:1012–22.
47. Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, Anderson KE, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. *J Natl Cancer Inst* 2006;98:1731–8.
48. Slattery ML, Curtin K, Sweeney C, Levin TR, Potter J, Wolff RK, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. *Int J Cancer* 2007;120:656–63.
49. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell* 2010;18:553–67.
50. East JE, Saunders BP, Jass JR. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. *Gastroenterol Clin North Am* 2008;37:25–46.
51. Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. *Carcinogenesis* 2008;29:673–80.
52. Snover DC. Serrated polyps of the large intestine. *Semin Diagn Pathol* 2005;22:301–8.
53. Snover DC. Update on the serrated pathway to colorectal carcinoma. *Hum Pathol* 2011;42:1–10.
54. Carragher LA, Snell KR, Giblett SM, Aldridge VS, Patel B, Cook SJ, et al. V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. *EMBO Mol Med* 2010;2:458–71.
55. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. *Proc Natl Acad Sci U S A* 1998;95:6870–5.
56. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. *Nat Genet* 2006;38:787–93.
57. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. *J Mol Diagn* 2007;9:305–14.
58. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. *Genome Res* 2012;22:271–82.
59. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. *J Mol Diagn* 2006;8:582–8.
60. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. *Proc Natl Acad Sci U S A* 2007;104:18654–9.
61. Yagi K, Akagi K, Hayashi H, Nagae G, Tsuji S, Isagawa T, et al. Three DNA methylation epigenotypes in human colorectal cancer. *Clin Cancer Res* 2010;16:21–33.
62. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. *Cancer Res* 2008;68:8541–6.
63. Dahlin AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklof V, Rutegard J, et al. The role of the CpG island methylator phenotype

- in colorectal cancer prognosis depends on microsatellite instability screening status. *Clin Cancer Res* 2010;16:1845–55.
64. Yamamoto E, Suzuki H, Yamano HO, Maruyama R, Nojima M, Kamimae S, et al. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. *Am J Pathol* 2012;181:1847–61.
  65. Peterson LM, Kipp BR, Halling KC, Kerr SE, Smith DI, Distad TJ, et al. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis. *Int J Gynecol Pathol* 2012;31:195–205.
  66. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. *Nat Genet* 2011;43:1262–5.
  67. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. *Cell* 2012;150:1135–46.
  68. Zouridis H, Deng N, Ivanova T, Zhu Y, Wong B, Huang D, et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. *Sci Transl Med* 2012;4:156ra40.
  69. Jithesh PV, Risk JM, Schache AG, Dhanda J, Lane B, Liloglou T, et al. The epigenetic landscape of oral squamous cell carcinoma. *Br J Cancer* 2013;108:370–9.
  70. Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. *Cancer Res* 2006;66:7490–501.
  71. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF, et al. A microarray-based DNA methylation study of glioblastoma multiforme. *Epigenetics* 2009;4:255–64.
  72. Martinez R, Schackert G, Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. *J Neurooncol* 2007;82:133–9.
  73. Nagarajan RP, Costello JF. Epigenetic mechanisms in glioblastoma multiforme. *Semin Cancer Biol* 2009;19:188–97.
  74. Stone AR, Bobo W, Brat DJ, Devi NS, Van Meir EG, Vertino PM. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. *Am J Pathol* 2004;165:1151–61.
  75. Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifemberger G, et al. Frequent promoter hypermethylation and transcriptional down-regulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. *Int J Cancer* 2008;123:2080–6.
  76. Uhlmann K, Rohde K, Zeller C, Szymas J, Vogel S, Marczynek K, et al. Distinct methylation profiles of glioma subtypes. *Int J Cancer* 2003;106:52–9.
  77. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 2009;462:739–44.
  78. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? *Lancet Oncol* 2011;12:83–91.
  79. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Collier HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell* 2010;17:225–34.
  80. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. *Cancer Cell* 2011;19:17–30.
  81. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. *Nature* 2012;483:484–8.
  82. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. *Nature* 2012;488:656–9.
  83. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. *Nat Genet* 2011;43:1256–61.
  84. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. *J Pathol* 2011;224:334–43.
  85. Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. *Biochem Biophys Res Commun* 2010;393:555–9.
  86. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. *Oncologist* 2012;17:72–9.
  87. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. *Oncogene* 2013;32:3091–100.
  88. Shabata T KA, Miyamoto M, Sasajima Y, Yamazaki M. Mutant IDH1 confers an *in vivo* growth in a melanoma cell line with BRAF mutation. *Am J Pathol* 2011;178:1395–492.
  89. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. *Hum Mutat* 2009;30:7–11.
  90. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. *J Natl Cancer Inst* 2010;102:932–41.
  91. Gaudet MM, Campan M, Figueroa JD, Yang XR, Lissowska J, Peplonska B, et al. DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations. *Cancer Epidemiol Biomarkers Prev* 2009;18:3036–43.
  92. Lee JS, Fackler MJ, Lee JH, Choi C, Park MH, Yoon JH, et al. Basal-like breast cancer displays distinct patterns of promoter methylation. *Cancer Biol Ther* 2010;9:1017–24.
  93. Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, Futscher BW. Agglomerative epigenetic aberrations are a common event in human breast cancer. *Cancer Res* 2008;68:8616–25.
  94. Van der Auwera I, Bovie C, Svensson C, Limame R, Trinh XB, van Dam P, et al. Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes. *Cancer Biol Ther* 2009;8:2252–9.
  95. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. *Nature* 2012;483:474–8.
  96. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. *Hum Mutat* 2012;33:100–3.
  97. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. *Nat Genet* 2011;43:1219–23.
  98. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. *Nat Genet* 2012;44:570–4.
  99. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. *Gut* 2011;60:397–411.
  100. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. *J Natl Cancer Inst* 2010;102:365–7.
  101. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 1998;58:5248–57.